SGLT2 inhibitor-related AEs differ with heart failure and diabetes

被引:0
|
作者
机构
关键词
D O I
10.1007/s40278-024-69291-8
中图分类号
学科分类号
摘要
引用
收藏
页码:11 / 11
相关论文
共 50 条
  • [41] Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure
    Cho, S.
    Oh, C. M.
    Kim, H.
    Park, S.
    Ko, Y. G.
    EUROPEAN HEART JOURNAL, 2018, 39 : 573 - 573
  • [42] Risk factors associated with SGLT2 inhibitor discontinuation in diabetic patients with heart failure
    Kim, Minkwan
    Heo, Seok-Jae
    Kim, Moon-Hyun
    Park, Je-Wook
    Bae, Sunga
    Roh, Ji Woong
    Lee, Oh-Hyun
    Kim, Yongcheol
    Im, Eui
    Jung, In Hyun
    Cho, Deok-Kyu
    PLOS ONE, 2024, 19 (11):
  • [43] Influence on urination of SGLT2 inhibitor in type 2 diabetes
    Sasaki, Junko
    Shikuma, Junpei
    Ito, Rokuro
    Odawara, Masato
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S98 - S98
  • [45] DAPAGLIFLOZIN, AN SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Demaris, K. M.
    White, J. R.
    DRUGS OF TODAY, 2013, 49 (05) : 289 - 301
  • [46] SGLT2 inhibition and heart failure—current concepts
    Joaquim Silva Custodio
    Andre Rodrigues Duraes
    Marconi Abreu
    Natalia Albuquerque Rocha
    Leonardo Roever
    Heart Failure Reviews, 2018, 23 : 409 - 418
  • [47] SGLT2 inhibitors and heart failure — clinical implications
    Itamar Raz
    Avivit Cahn
    Nature Reviews Cardiology, 2016, 13 : 185 - 186
  • [48] SGLT2 inhibitors as the bedrock of therapy for heart failure
    Tuttle, Katherine R.
    Rangaswami, Janani
    LANCET, 2022, 400 (10354): : 711 - 713
  • [49] SGLT2 inhibitors and heart failure - clinical implications
    Raz, Itamar
    Cahn, Avivit
    NATURE REVIEWS CARDIOLOGY, 2016, 13 (04) : 185 - 186
  • [50] Minireview: are SGLT2 inhibitors heart savers in diabetes?
    Rotkvic, Petra Grubic
    Berkovic, Maja Cigrovski
    Bulj, Nikola
    Rotkvic, Luka
    HEART FAILURE REVIEWS, 2020, 25 (06) : 899 - 905